WallStSmart
BGLC

BioNexus Gene Lab Corp Common stock

NASDAQ: BGLC · BASIC MATERIALS · SPECIALTY CHEMICALS

$2.09
+1.46% today

Updated 2026-04-30

Market cap
$5.37M
P/E ratio
P/S ratio
0.72x
EPS (TTM)
$-1.61
Dividend yield
52W range
$2 – $16
Volume
0.0M

BioNexus Gene Lab Corp Common stock (BGLC) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2016201720182019202020212022202320242025
Revenue$107680.00$212328.00$126955.00$11.39M$13.36M$10.93M$9.77M$9.51M$7.42M
Revenue growth (YoY)+97.2%-40.2%+8872.0%+17.3%-18.2%-10.6%-2.7%-21.9%
Cost of revenue$28871.00$183563.00$71067.00$9.67M$11.17M$9.67M$8.44M$8.22M$6.34M
Gross profit$78809.00$28765.00$55888.00$1.72M$2.19M$1.26M$1.33M$1.29M$1.09M
Gross margin73.2%13.5%44.0%15.1%16.4%11.5%13.6%13.6%14.6%
R&D$54982.00$47511.00$50670.00
SG&A$241930.00$356641.00$1.33M$1.20M$1.73M$2.44M$1.97M$2.33M
Operating income$-840.00$-127910.00$59901.00$-275705.00$1.27M$1.06M$-291177.00$-2.59M$-1.57M$-3.16M
Operating margin-118.8%28.2%-217.2%11.2%7.9%-2.7%-26.5%-16.5%-42.5%
EBITDA$-104383.00$100512.00$-222373.00$1.38M$1.16M$-185761.00$-2.49M$-1.42M$-2.80M
EBITDA margin-96.9%47.3%-175.2%12.1%8.7%-1.7%-25.4%-14.9%-37.7%
EBIT$-119414.00$59901.00$-275705.00$1.27M$1.06M$-291180.00$-2.59M$-1.57M$-2.97M
Interest expense$0.00$0.00$0.00$0.00$11313.00$12973.00$12479.00$13929.00$21146.00$19542.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-835.00$-123750.00$26454.00$-246469.00$1.09M$751571.00$-355966.00$-2.63M$-1.60M$-2.98M
Net income growth (YoY)-14720.4%+121.4%-1031.7%+543.9%-31.3%-147.4%-638.6%+39.2%-86.7%
Profit margin-114.9%12.5%-194.1%9.6%5.6%-3.3%-26.9%-16.8%-40.2%